A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma.

Trial Profile

A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Azacitidine (Primary) ; Temozolomide (Primary)
  • Indications Mesothelioma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jun 2014 Interim results (n=28) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 07 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Planned end date changed from 1 Aug 2011 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top